Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen
(CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the
visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days
before surgery and visualized using an optimized camera system.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Surgimab
Collaborators:
Catharina Ziekenhuis Eindhoven Centre for Human Drug Research, Netherlands Erasmus Medical Center Leiden University Medical Center